|
Investment in Saneron CCEL Therapeutics, Inc. (''Saneron'') - Additional Information (Detail) (USD $)
|
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
|
May 31, 2013
|
May 31, 2012
|
May 31, 2013
|
May 31, 2012
|
Nov. 30, 2012
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
| Value of treasury stock | $ 2,855,471 | $ 2,855,471 | $ 2,187,505 | ||
|
Saneron [Member]
|
|||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
| Ownership interest | 34.00% | 34.00% | 34.00% | ||
| Goodwill | 684,000 | 684,000 | 684,000 | ||
| Goodwill Impairment | 0 | 0 | |||
| Equity in losses of Saneron operations | 38,000 | 39,000 | 77,000 | 78,000 | |
| Value of treasury stock | $ 485,000 | $ 485,000 | $ 485,000 | ||
| X | ||||||||||
|
- Definition
Investments in affiliates equity in aggregate losses. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|